Supplemental material
Report
Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro
, 
, , , , , , , , , , & show all
Emma J. Suttona UCB Pharma, Berkshire, UKhttps://orcid.org/0000-0001-6311-1451View further author information
https://orcid.org/0000-0001-6311-1451View further author information, , , , , , , Nicholas M. Barnesb Celentyx Ltd, Birmingham Research Park, Birmingham, UKhttps://orcid.org/0000-0003-4624-9672View further author information
https://orcid.org/0000-0003-4624-9672View further author information, , , & Anthony Shocka UCB Pharma, Berkshire, UKCorrespondence[email protected]
https://orcid.org/0000-0002-9971-8789View further author information
https://orcid.org/0000-0002-9971-8789View further author information show all